← Leaderboards
Kevan C Herold
Columbia University Health Sciences
$39,325,259
Attributed
$44,695,433
Total exposure
33
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$58,396,971 · 35
By mechanism
R01$17,053,334 · 5
P30$14,647,024 · 4
U01$9,067,206 · 3
U19$4,466,368 · 3
T32$3,987,350 · 3
UC4$2,496,787 · 1
Top collaborators
- Harriet M Kluger7 shared
- Gerald I Shulman7 shared
- Joseph E Craft5 shared
- David A. Hafler5 shared
- Sonia Caprio2 shared
- John J Wysolmerski2 shared
- Mark J. Mamula1 shared
- Sahar Usmani-Brown1 shared
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusClinical ResearchPreventInsulin-Dependent Diabetes MellitusResponseSamplingCellsInsulinImmunotherapyImmuneAffectBaseT-LymphocyteClinical TrialsResearch PersonnelPhenotypeImmunologicsAntigensCollaborationsBeta CellFundingCd3 AntigensLeadImmune Response
Grant awards (133)
Advanced pancreatic-immune organoid models of type 1 diabetes subtypes and therapeutic responses$1,201,988
UG3 · FY2025 · DK · contact PI
Yale Diabetes Research Center$1,131,880
P30 · FY2025 · DK
Modulating pathogenic T cells in Type 1 diabetes$716,366
R01 · FY2025 · DK · contact PI
Diabetes Mellitus and Disorders of Metabolism$577,479
T32 · FY2025 · DK
Human and Translational Immunology Training Program$474,931
T32 · FY2025 · AI · contact PI
Pilot & Feasibility Core$374,613
P30 · FY2025 · DK · contact PI
Yale Diabetes Research Center$1,151,723
P30 · FY2024 · DK
Modulating pathogenic T cells in Type 1 diabetes$722,908
R01 · FY2024 · DK · contact PI
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes$644,903
R01 · FY2024 · DK · contact PI
Human and Translational Immunology Training Program$444,717
T32 · FY2024 · AI · contact PI
Pilot & Feasibility Core$374,611
P30 · FY2024 · DK · contact PI
Diabetes Mellitus and Disorders of Metabolism$200,664
T32 · FY2024 · DK
Yale Diabetes Research Center$1,165,890
P30 · FY2023 · DK
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes$671,775
R01 · FY2023 · DK · contact PI
Human and Translational Immunology Training Program$424,278
T32 · FY2023 · AI · contact PI
Modulating pathogenic T cells in Type 1 diabetes$383,940
R01 · FY2023 · DK · contact PI
Pilot & Feasibility Core$374,613
P30 · FY2023 · DK · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2022 · DK
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes$679,061
R01 · FY2022 · DK · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$554,845
R01 · FY2022 · CA · contact PI
Human and Translational Immunology Training Program$447,743
T32 · FY2022 · AI · contact PI
Modulating pathogenic T cells in Type 1 diabetes$384,483
R01 · FY2022 · DK · contact PI
Pilot and Feasibility Program$343,210
P30 · FY2022 · DK · contact PI
Effects of EBV on autoimmunity and responses to immune therapy$209,375
R21 · FY2022 · AI · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2021 · DK
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes$712,811
R01 · FY2021 · DK · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$580,072
R01 · FY2021 · CA · contact PI
Human and Translational Immunology Training Program$423,158
T32 · FY2021 · AI · contact PI
Modulating pathogenic T cells in Type 1 diabetes$422,823
R01 · FY2021 · DK · contact PI
Pilot and Feasibility Program$343,213
P30 · FY2021 · DK · contact PI
Effects of EBV on autoimmunity and responses to immune therapy$251,250
R21 · FY2021 · AI · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2020 · DK
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$585,633
R01 · FY2020 · CA · contact PI
Modulating pathogenic T cells in Type 1 diabetes$431,038
R01 · FY2020 · DK · contact PI
Pilot and Feasibility Program$343,211
P30 · FY2020 · DK · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2019 · DK
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$568,064
R01 · FY2019 · CA · contact PI
Modulating pathogenic T cells in Type 1 diabetes$491,898
R01 · FY2019 · DK · contact PI
Pilot and Feasibility Program$343,213
P30 · FY2019 · DK · contact PI
Mechanisms of Autoimmune Diabetes in Patients Treated with Immune checkpoint Inhibitors$125,625
R21 · FY2019 · AI · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$81,816
R01 · FY2019 · CA · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$580,767
R01 · FY2018 · CA · contact PI
Type 1 diabetes TrialNet Center at Yale University$358,419
U01 · FY2018 · DK · contact PI
Pilot and Feasibility Program$343,212
P30 · FY2018 · DK · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$293,469
R01 · FY2018 · CA · contact PI
Autoimmunity to Protein Modifications in Checkpoint Inhibitor Induced and Spontaneous T1D$167,500
R01 · FY2018 · DK
Mechanisms of Autoimmune Diabetes in Patients Treated with Immune checkpoint Inhibitors$125,625
R21 · FY2018 · AI · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$329,053
R01 · FY2017 · DK · contact PI
PILOT AND FEASIBILITY PROGRAM$327,051
P30 · FY2017 · DK · contact PI
Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy$299,754
R43 · FY2017 · DK
Type 1 diabetes TrialNet Center at Yale University$265,526
U01 · FY2017 · DK · contact PI
The role of the innate immune system on Treg reprogramming in human autoimmune di$721,853
U01 · FY2016 · AI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$329,053
R01 · FY2016 · DK · contact PI
PILOT AND FEASIBILITY PROGRAM$327,051
P30 · FY2016 · DK · contact PI
Type 1 diabetes TrialNet Center at Yale University$265,526
U01 · FY2016 · DK · contact PI
Phase II trial of extended release exenatide (Bydureon) and teplizumab in patients with new onset Type 1 Diabetes.$251,250
R34 · FY2016 · AI · contact PI
The role of the innate immune system on Treg reprogramming in human autoimmune di$742,405
U01 · FY2015 · AI
Measurement of Beta Cell Death in Diabetes$686,590
R42 · FY2015 · DK · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$333,406
R01 · FY2015 · DK · contact PI
PILOT AND FEASIBILITY PROGRAM$327,051
P30 · FY2015 · DK · contact PI
Type 1 diabetes TrialNet Center at Yale University$265,526
U01 · FY2015 · DK · contact PI
Epigenetic, Protein, and Cellular Biomarkers of Beta Cell Function in T1D$2,496,787
UC4 · FY2014 · DK · contact PI
The role of the innate immune system on Treg reprogramming in human autoimmune di$762,141
U01 · FY2014 · AI
Measurement of Beta Cell Death in Diabetes$661,513
R42 · FY2014 · DK · contact PI
Type 1 diabetes TrialNet Center at Yale University$370,829
U01 · FY2014 · DK · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$341,325
R01 · FY2014 · DK · contact PI
PILOT AND FEASIBILITY PROGRAM$327,051
P30 · FY2014 · DK · contact PI
Human and Translational Immunology$179,237
T32 · FY2014 · AI · contact PI
Analysis of beta cell death in Type 1 diabetes$806,617
DP3 · FY2013 · DK · contact PI
The role of the innate immune system on Treg reprogramming in human autoimmune di$734,063
U01 · FY2013 · AI
Yale Autoimmunity Center of Excellence$653,897
U19 · FY2013 · AI · contact PI
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)$462,733
U01 · FY2013 · DK · contact PI
PILOT AND FEASIBILITY PROGRAM$349,439
P30 · FY2013 · DK · contact PI
Human and Translational Immunology$238,845
T32 · FY2013 · AI · contact PI
Administrative Core A, Component of Yale Autoimmunity Center of Excellence$126,663
U19 · FY2013 · AI · contact PI
The role of the innate immune system on Treg reprogramming in human autoimmune di$815,616
U01 · FY2012 · AI
Yale Autoimmunity Center of Excellence$704,980
U19 · FY2012 · AI · contact PI
Measurement of Beta Cell Death in Diabetes$284,931
R41 · FY2012 · DK · contact PI
Human and Translational Immunology$228,186
T32 · FY2012 · AI · contact PI
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)$154,546
U01 · FY2012 · DK · contact PI
Administrative Core A, Component of Yale Autoimmunity Center of Excellence$140,850
U19 · FY2012 · AI · contact PI
Yale Autoimmunity Center of Excellence$719,597
U19 · FY2011 · AI · contact PI
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)$334,074
U01 · FY2011 · DK · contact PI
Human and Translational Immunology$234,062
T32 · FY2011 · AI · contact PI
Administrative Core A, Component of Yale Autoimmunity Center of Excellence$146,255
U19 · FY2011 · AI · contact PI
Yale Autoimmunity Center of Excellence$737,303
U19 · FY2010 · AI · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$542,608
R01 · FY2010 · DK · contact PI
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)$430,530
U01 · FY2010 · DK · contact PI
Innate and Adaptive Immune Responses in Pre-type 1 Diabetes$399,089
RC4 · FY2010 · DK · contact PI
Administrative Core A, Component of Yale Autoimmunity Center of Excellence$149,853
U19 · FY2010 · AI · contact PI
Human and Translational Immunology$114,050
T32 · FY2010 · AI · contact PI
Yale Autoimmunity Center of Excellence$736,276
U19 · FY2009 · AI · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$501,924
R01 · FY2009 · DK · contact PI
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)$405,705
U01 · FY2009 · DK · contact PI
Administrative Core A, Component of Yale Autoimmunity Center of Excellence$150,528
U19 · FY2009 · AI · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$30,730
R01 · FY2009 · DK · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$489,149
R01 · FY2008 · DK · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$540,834
R01 · FY2007 · DK · contact PI
Type 1 Diabetes TrialNet: Clinical Center at Columbia University$426,894
U01 · FY2007 · DK · contact PI
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes$558,710
R01 · FY2006 · DK · contact PI
Type 1 Diabetes TrialNet: Clin Ctr at Columbia Universi*$1
U01 · FY2006 · DK · contact PI
Combination of Anti-CD3 and Ag-Specific Immunotherapy$437,250
R21 · FY2005 · DK
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in IDDM$227,298
R01 · FY2005 · DK
Type 1 Diabetes TrialNet: Clin Ctr at Columbia Universi*$215,911
U01 · FY2005 · DK
Islet Growth in NOD Mice Tolerant to Autoimmune Diabetes$208,395
R01 · FY2005 · DK
Islet Growth in NOD Mice Tolerant to Autoimmune Diabetes$78,407
R01 · FY2005 · DK
SAFETY AND PK OF HOKT3YL (ALA-ALA) IN TIDM$21,290
M01 · FY2005 · RR
ISLET TRANSPLANTS WITH RENAL ALLOGRAFTS$7,742
M01 · FY2005 · RR
PHASE II MULTIPLE DOSE TREATMENT OF TYPE 1 DIABETES MELLITUS WITH HOKT3GAMMAL$3,225
M01 · FY2005 · RR
HOKT3YL(ALA-ALA) IN NEW ONSET TYPE 1 DIABETES MELLITUS$645
M01 · FY2005 · RR
PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES$526,914
R01 · FY2004 · DK
Combination of Anti-CD3 and Ag-Specific Immunotherapy$467,750
R21 · FY2004 · DK
Type 1 Diabetes TrialNet: Clin Ctr at Columbia Universi*$355,643
U01 · FY2004 · DK
Islet Growth in NOD Mice Tolerant to Autoimmune Diabetes$281,750
R01 · FY2004 · DK
Phase II Multiple Dose Treatment of Type 1 Diabetes Mellitus with hOKT3gammal$3,610
M01 · FY2004 · RR
hOKT3yl(Ala-Ala) in New Onset Type 1 Diabetes Mellitus$2,499
M01 · FY2004 · RR
PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES$515,514
R01 · FY2003 · DK
Type 1 Diabetes TrialNet: Clin Ctr at Columbia Universi*$326,720
U01 · FY2003 · DK
PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES$511,279
R01 · FY2002 · DK
Type 1 Diabetes TrialNet: Clin Ctr at Columbia Universi*$331,094
U01 · FY2002 · DK
HOKT3YL (ALA ALA) IN NEW ONSET TYPE I DIABETES MELLITUS$192,910
M01 · FY2002 · RR
PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES$17,686
R01 · FY2002 · DK
T cell activation and repertoire in insulin dependent diabetes / anti CD40L trial$0
U19 · FY2002 · AI
PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES$496,912
R01 · FY2001 · DK
Type 1 Diabetes TrialNet:Columbia University$321,451
U01 · FY2001 · DK
HOKT3YL (ALA ALA) IN NEW ONSET TYPE I DIABETES MELLITUS$192,910
M01 · FY2001 · RR
T cell activation and repertoire in insulin dependent diabetes / anti CD40L trial$0
U19 · FY2001 · AI
HOKT3YL (ALA ALA) IN NEW ONSET TYPE I DIABETES MELLITUS$0
M01 · FY2001 · RR
PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES$518,215
R01 · FY2000 · DK
T cell activation and repertoire in insulin dependent diabetes / anti CD40L trial$200,166
U19 · FY2000 · AI
CLINICAL RESEARCH TRAINING IN IMMUNOSUPPRESSION AND DIAB$45,464
R25 · FY2000 · RR
HOKT3YL (ALA ALA) IN NEW ONSET TYPE I DIABETES MELLITUS$0
M01 · FY2000 · RR
HOKT3YL (ALA ALA) IN NEW ONSET TYPE I DIABETES MELLITUS$0
M01 · FY2000 · RR